Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma

Sa Ra Lee, Kyong Wook Yi, Jae Yen Song, Seok Kyo Seo, Dong-Yun Lee, Dong‐Yun Lee, SiHyun Cho, Sung Hoon Kim
Reproductive sciences (Thousand Oaks, Calif.) · 2017 · vol. 25(3) , pp. 341–346 · doi:10.1177/1933719117725820 · PMID:29161960 · W2768613407
article OA: green CC0 ⤵ 30 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This study investigated the long-term efficacy and safety of daily oral dienogest in women with ovarian endometrioma, finding a low recurrence rate, significant pain reduction, and amenorrhea.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This retrospective multicenter cohort study evaluated the long-term efficacy and safety of daily 2 mg oral dienogest in 514 women with ovarian endometrioma, with treatment administered for at least 48 weeks after surgery across 7 university-affiliated hospitals. During continued dienogest use, ultrasound-determined recurrence of endometrioma, adverse events, menstrual pattern changes, and pain scores (visual analogue scale) were tracked over an average duration of 72.2 weeks (range 48–164), with key limitations being its retrospective design and lack of a randomized comparator group. The recurrence rate was 1.8% (9/514), pain improved for 82.2% of patients, mean VAS scores decreased significantly from 4.9 at baseline to lower values at multiple time points, and amenorrhea increased over time. This paper is centrally about endometriosis — specifically, long-term dienogest effects on recurrence and pain in women with ovarian endometrioma.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,146 characters · extracted from oa-html · click to expand
YUHASpace Repository 0 841 Cited 0 times in Cited 39 times in Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma - Authors - Sa Ra Lee ; Kyong Wook Yi ; Jae Yen Song ; Seok Kyo Seo ; Dong-Yun Lee ; SiHyun Cho ; Sung Hoon Kim - Citation - REPRODUCTIVE SCIENCES, Vol.25(3) : 341-346, 2018 - Journal Title - REPRODUCTIVE SCIENCES - ISSN - 1933-7191 - Issue Date - 2018 - Keywords - Dienogest ; endometriosis ; progestin - Abstract - Dienogest (DNG) is a progestin with highly selective progesterone activity and minimal androgenic activity and is helpful in reducing endometriosis-related pain. This study assessed the long-term efficacy and safety and recurrence rate of endometrioma with DNG use beyond 12 months of treatment. A retrospective cohort study was conducted with data collected from 7 university-affiliated hospitals and included a total of 514 women with ovarian endometrioma. All patients received 2 mg of oral DNG daily for at least 48 weeks postoperatively. During continuation of DNG, the recurrence rate of ovarian endometrioma on ultrasound, adverse events, changes in menstrual pattern, and pain score (visual analogue scale) were analyzed. The average period of DNG administration in this study was 72.2 +/- 5.2 weeks (range: 48-164). The recurrence rate of endometrioma was 1.8% (9 of 514), and the median duration to recurrence was 58 weeks (range: 24-76). Pain was described as overall improved by 82.2% of patients; 61.6% stated the pain was "improved" and 20.6% reported "much improved." The mean VAS score was 4.9 at baseline and significantly decreased to 2.68, 2.2, 1.6, and 2.6 at 12, 24, 48, and 96 weeks. Amenorrhea rate was 58.3% in the first 12 weeks and increased to 86.4% at 72 weeks. Prolonged daily administration of 2 mg DNG followed by surgery was associated with a lower recurrence rate of ovarian endometrioma and a reduced pain score and symptoms. - Appears in Collections: - 1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715endometrioma

MeSH descriptors

Endometriosis Hormone Antagonists Nandrolone Ovarian Diseases Adult Endometriosis Endometriosis Female Hormone Antagonists Hormone Antagonists Humans Middle Aged Nandrolone Nandrolone Nandrolone Ovarian Diseases Ovarian Diseases Pain Measurement Recurrence Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Cited by (30)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:07.505861+00:00
License: CC0 · commercial use OK